Extended Data Fig. 5: Overview of number of regions sampled, stage, treatment and ITH metrics including mutational ITH, SCNA ITH and whole genome doubling status for 432 tumours from 421 patients in TRACERx.
From: The evolution of lung cancer and impact of subclonal selection in TRACERx

Each tumour is arranged vertically ordered first by pathological stage then by fraction of subclonal subclonal mutations. LCNEC = Large cell neuroendocrine carcinoma, CN = copy number.